Cohance Lifesciences Limited announced its results for the quarter ended June 30, 2025, its first full quarter operating under the new name.

Revenue was Rs.549.3 crore, up 13 per cent year-on-year. Excluding temporary inventory destocking in Pharma CDMO, growth exceeded 25 per cent. Gross margin rose to 73 per cent from 68.4 per cent last year, driven by a richer mix of niche technologies and contributions from recent acquisitions. Adjusted EBITDA was Rs. 131.4 crore with a margin of 23.9 per cent, reflecting planned investments in high-value modalities, talent, and integration of NJ Bio and Sapala.

Niche technology revenues crossed 20 per cent of total sales, compared to mid-teens in FY25, and are expected to reach mid-20s by year-end. Pharma CDMO revenue grew over 30 per cent excluding destocking. Specialty Chemicals rose 28 per cent on AgChem recovery and new projects, while API+ grew 19 per cent on strong execution and new launches.

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site and a Rs.23 crore oligonucleotide building block facility in Hyderabad, expected to be operational by end-CY25.

The company received an early-phase integrated payload-linker synthesis and bioconjugation order from a U.S. partner and started developing a new OEB6 high-containment block for a major innovator’s payload program in India. It also secured a life cycle management contract for a branded API and added four new large global innovators to its customer base.

Cohance appointed Yann D’Hervé as CEO of its CDMO business and formed an External Advisory Board of five global pharma leaders to guide its growth in high-value modalities.

Vivek Sharma, Executive Chairman, said: “Q1FY26 has been an important start to the year, with progress not just in execution but in strengthening the foundation we have built. Our growing presence in niche modalities like ADCs and oligonucleotides, combined with a deepening global customer base, positions Cohance for accelerated growth. With strengthened leadership and the guidance of our External Advisory Board, we remain committed to becoming a global technology-led CDMO, delivering long-term value for all stakeholders.”

Cohance Lifesciences, formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals, operates state-of-the-art facilities in India and the U.S., providing integrated solutions from early development to commercial supply for leading global pharma companies.